Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A
(2013)
J Clin Oncol 31: 1767-74
MeSH Terms: Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Apoptosis, Cell Cycle, Cell Proliferation, Disease Progression, Drug Resistance, Neoplasm, Female, GTP Phosphohydrolases, Humans, Immunohistochemistry, Indoles, MAP Kinase Kinase 1, MAP Kinase Signaling System, Male, Melanoma, Membrane Proteins, Middle Aged, Mitogen-Activated Protein Kinase Kinases, Point Mutation, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Sulfonamides, Tumor Cells, Cultured, VemurafenibAdded March 5, 2014